• Anixa Biosciences announced on July 6th that its ovarian cancer CAR-T clinical trial advanced to its highest dose level to date, with no dose-limiting toxicities observed and positive survival data for multiple patients.
  • Shares are trading at $2.84 (-6.9%) in pre-market, extending a multi-day pullback after a significant rally last week.
  • The current decline appears to be driven by profit-taking and broader market sentiment, potentially a "sell the news" reaction following the recent clinical trial milestone.